Paper Details

  1. Home
  2. Paper Details

The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Granisetron, a serotonin antagonist, was compared to metoclopramide plus dexamethasone for preventing nausea and vomiting in patients receiving chemotherapy. The study found that granisetron was equally effective as the combination therapy, with similar complete response rates (no vomiting, no worse than mild nausea) and fewer treatment failures. Importantly, granisetron was associated with fewer side effects, including a significantly lower incidence of extrapyramidal syndrome (20.6% for metoclopramide plus dexamethasone versus none for granisetron).
Paper Details　
Original Abstract of the Article :
The antiemetic efficacy and safety of granisetron (40 micrograms/kg), a selective and potent 5-hydroxytryptamine (serotonin) antagonist, was compared with that of metoclopramide (7 mg/kg) plus dexamethasone (12 mg) in patients receiving fractionated chemotherapy. Patients receiving cisplatin at dose...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01686466

データ提供：米国国立医学図書館（NLM）

The Antiemetic Arms Race: Granisetron vs. Metoclopramide Plus Dexamethasone

Chemotherapy, a powerful weapon in the fight against cancer, can also be accompanied by unpleasant side effects. Nausea and vomiting, a common challenge for patients undergoing chemotherapy, can make the treatment journey a difficult one. Imagine chemotherapy as a battle against a formidable desert enemy, where the side effects of nausea and vomiting are like the scorching desert sun. This research explores the antiemetic efficacy and safety of granisetron, a serotonin antagonist, compared to metoclopramide plus dexamethasone, a common antiemetic combination. The study finds that granisetron offers comparable efficacy with a favorable safety profile, potentially providing a more comfortable treatment experience for patients.

A More Comfortable Desert: The Advantage of Granisetron

The study demonstrates that granisetron is at least as effective as metoclopramide plus dexamethasone in preventing nausea and vomiting in patients undergoing chemotherapy. This finding suggests that granisetron may be a preferred treatment option for many patients, offering a more comfortable and tolerable treatment experience. It's like finding a cool, shady oasis in the midst of the desert heat, offering a respite from the harsh conditions.

Navigating the Treatment Journey: Choosing the Right Weapon

The research highlights the importance of selecting the right antiemetic medication for individual patients, ensuring the most comfortable and effective treatment experience. It's like choosing the right weapon for a desert battle, ensuring a safe and successful journey.

Dr. Camel's Conclusion

This study provides valuable insights into the antiemetic efficacy and safety of granisetron, offering a new perspective on the management of chemotherapy-induced nausea and vomiting. The findings suggest that granisetron may be a preferred treatment option for many patients, offering a more comfortable and tolerable treatment experience.

Date :
  1. Date Completed 1993-08-09
  2. Date Revised 2019-09-04
Further Info :

Pubmed ID

8392077

DOI: Digital Object Identifier

10.1007/BF01686466

Related Literature

Article Analysis
・Effects of granisetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.